title: Silencing of RUNX2 enhances gemcitabine sensitivity of p53-deficient human pancreatic cancer AsPC-1 cells through the stimulation of TAp63-mediated cell death.
authors.affiliation: Laboratory of DNA Damage Signaling, Chiba Cancer Center Research Institute, 666-2 Nitona, Chuou-ku, Chiba 260-8717, Japan.
authors.forename: H
authors.initials: H
authors.lastname: Sugimoto
authors.affiliation: Laboratory of DNA Damage Signaling, Chiba Cancer Center Research Institute, 666-2 Nitona, Chuou-ku, Chiba 260-8717, Japan.
authors.forename: M
authors.initials: M
authors.lastname: Nakamura
authors.affiliation: Laboratory of Cancer Genetics, Chiba Cancer Center Research Institute, 666-2 Nitona, Chuou-ku, Chiba 260-8717, Japan.
authors.forename: H
authors.initials: H
authors.lastname: Yoda
authors.affiliation: Laboratory of Cancer Genetics, Chiba Cancer Center Research Institute, 666-2 Nitona, Chuou-ku, Chiba 260-8717, Japan.
authors.forename: K
authors.initials: K
authors.lastname: Hiraoka
authors.affiliation: Laboratory of Cancer Genetics, Chiba Cancer Center Research Institute, 666-2 Nitona, Chuou-ku, Chiba 260-8717, Japan.
authors.forename: K
authors.initials: K
authors.lastname: Shinohara
authors.affiliation: Laboratory of DNA Damage Signaling, Chiba Cancer Center Research Institute, 666-2 Nitona, Chuou-ku, Chiba 260-8717, Japan.
authors.forename: M
authors.initials: M
authors.lastname: Sang
authors.affiliation: Innovative Therapy Research Group, Nihon University Research Institute of Medical Science, Nihon University School of Medicine, 30-1 Oyaguchi-Kamicho, Itabashi, Tokyo 173-8610, Japan.
authors.forename: K
authors.initials: K
authors.lastname: Fujiwara
authors.affiliation: Laboratory of DNA Damage Signaling, Chiba Cancer Center Research Institute, 666-2 Nitona, Chuou-ku, Chiba 260-8717, Japan.
authors.forename: O
authors.initials: O
authors.lastname: Shimozato
authors.affiliation: Laboratory of Cancer Genetics, Chiba Cancer Center Research Institute, 666-2 Nitona, Chuou-ku, Chiba 260-8717, Japan.
authors.forename: H
authors.initials: H
authors.lastname: Nagase
authors.affiliation: Laboratory of DNA Damage Signaling, Chiba Cancer Center Research Institute, 666-2 Nitona, Chuou-ku, Chiba 260-8717, Japan.
authors.forename: T
authors.initials: T
authors.lastname: Ozaki
mesh_terms: D000964:Antimetabolites, Antineoplastic / Q000494:pharmacology*; D017209:Apoptosis; D045744:Cell Line, Tumor; D050659:Core Binding Factor Alpha 1 Subunit / Q000235:genetics* / Q000378:metabolism; D003841:Deoxycytidine / Q000031:analogs & derivatives* / Q000494:pharmacology; D019008:Drug Resistance, Neoplasm; D055785:Gene Knockdown Techniques; D006801:Humans; D010190:Pancreatic Neoplasms / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology; D014157:Transcription Factors / Q000502:physiology*; D016159:Tumor Suppressor Protein p53 / Q000172:deficiency / Q000235:genetics; D025521:Tumor Suppressor Proteins / Q000502:physiology*; D000093542:Gemcitabine
chemical_list: D000964:Antimetabolites, Antineoplastic; D050659:Core Binding Factor Alpha 1 Subunit; C493709:RUNX2 protein, human; C495901:TP53 protein, human; C115051:TP63 protein, human; D014157:Transcription Factors; D016159:Tumor Suppressor Protein p53; D025521:Tumor Suppressor Proteins; D003841:Deoxycytidine; D000093542:Gemcitabine